PHARMACEUTICAL PREPARATIONS TREATING NEURODEGENERATIVE

Brand Owner (click to sort) Address Description
ACLARUSDX EXONHIT S.A. 63-65 boulevard Massena F-75013 PARIS France Pharmaceutical preparations for treating neurodegenerative diseases and particularly Alzheimer's disease; tests, namely, a blood based biomarker test to identify patients with Alzheimer's disease or at risk of developing the disease and identifying patients responding to specific treatments; biological products and preparations acids for pharmaceutical use, namely, pharmaceutical preparations for the diagnostic of the Alzheimer's disease; capsules sold empty for medicines and diagnostic tests; chemical-pharmaceutical preparations for the diagnosis, the prevention or the treatment of Alzheimer's disease; biopharmaceutical preparations for the diagnosis, the prevention or the treatment of Alzheimer's disease; chemical preparations for medical, pharmaceutical or veterinary use, namely, for diagnosing neurodegenerative diseases and particularly Alzheimer's disease; medical and clinical diagnostic products, namely, probe sets, namely, subset of nucleic acid sequences and nucleic acid libraries, namely, DNA libraries and RNA libraries; nucleic acid sequences for use on biochips, namely, for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease; enzymes or enzyme preparations for medical or veterinary use, namely, enzymes stabilizers, namely, enzymes for medical purposes or veterinary use, namely, for treatment of Alzheimer's disease, enzyme substrates, namely, enzymes for medical purposes or veterinary use, namely, for treatment of Alzheimer's disease used as an ingredient in drugs against Alzheimer's disease;Color is not claimed as a feature of the mark.;Chemicals and chemical compositions, namely, nucleic acids attached to a solid support for use in industry and science; analyses, namely, reagent for chemical analyses, namely, quantification of nucleic acid content in laboratories chemical preparations for analyses, other than for medical or veterinary use; biological preparations, namely, quantification of nucleic acid content other than for medical or veterinary use, namely, inoculants, namely, biological microorganisms used in fermentation of silage; chemical preparations for scientific use, other than for medical or veterinary use; chemical preparations or reagents for laboratory, other than for medical or veterinary use; chemical preparations for scientific use, namely, nucleic acid libraries to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, DNA biochips for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease, and DNA chips to make visible and analyze gene expression in the fields of human and pharmacological medicine and veterinary science;Medical services; veterinary services; medical assistance services; providing medical information, consultancy and advisory services; hospital services; pharmacists' services relating to the pharmaceutical industry, namely, the filling of and making up prescriptions; health care; telemedicine services;Surgical, medical, dental and veterinary apparatus and instruments, namely, for disease identification, measure of disease severity, measure of disease prognosis, measure of disease progression, measure of disease conversion; medical devices, namely, biochips for analysis of blood; blood testing apparatus; devices, namely, biochips for medical diagnostics uses, namely, biochips for diagnosing Alzheimer's disease, namely, collection kit for blood sampling to perform the test in the right conditions; spoons for administering medicine; receptacles for applying medicines; ultrasound probes for medical use; syringes for medical use; galvanic therapeutic medical devices to diagnose neurodegenerative diseases and particularly Alzheimer's disease;Research and development for third parties in relation to pharmaceutical molecules or biological markers, medicines for the diagnosis and treatment of neurodegenerative diseases; chemical analysis; chemical research; chemical services, namely, analysis of RNA, genes, tissue and blood sample; biotechnology project studies, namely, identifying population of patients affected by the Alzheimer disease and measuring the disease's severity, prognosis, progression and conversion and determining patients sensitivity to treatment; research and development of new products for third parties; biological research; research in biotechnology; technical research in the field of biotechnology; biotechnology analysis services;
BIOGRAPHENE BIOGRAPHENE 555 W 5TH ST. FL35 #35010 Los Angeles CA 90013 Pharmaceutical preparations for treating neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, lysosomal storage disorders, Niemann-Pick Type C Disease, cancer, Fibrosis diseases, Crohn' disease, and autoimmune disorders;
BRELODY ORION CORPORATION ORIONINTIE 1 ESPOO 02200 Finland Pharmaceutical preparations for treating neurodegenerative diseases;
CASSAVA SCIENCES CASSAVA SCIENCES, INC. Suite 260 7801 N. Capital of Texas Highway Austin TX 78731 Pharmaceutical preparations for treating neurodegenerative diseases; analgesic preparations; preparations for the relief of pain;SCIENCES;Product research and development; Pharmaceutical research and development; Scientific research for medical purposes in the field of neurodegenerative diseases;
NUREDIS Nuredis, Inc. Suite 1120 1455 Adams Drive Menlo Park CA 94025 Pharmaceutical preparations for treating neurodegenerative and neuromuscular diseases;The wording NUREDIS has no meaning in a foreign language.;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for treating secretory diarrhea. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients, and/or diluents.